Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | FABP3 | P05413 | 7/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11072297 | 0.97 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL431983 | 0.84 | NPSR1 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Bromide SCHEMBL431069 | 0.83 | NPSR1 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11072301 | 0.83 | NPSR1 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL431068 | 0.81 | HSP90AA1 (0.38) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13587656 | 0.79 | NPSR1 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9310464 | 0.78 | NPSR1 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10666125 | 0.78 | POLB (0.49) | PPARGPPARA | |
| SCHEMBL4139139 | 0.77 | NPSR1 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11663970 | 0.77 | ALDH1A1 (0.42) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157590-B2 | Chemical intermediate for vision defect drug | FINETECH LABORATORIES LTD. (IL) | 2007-01-02 | — | — | US | disclosed |
| US-6927300-B2 | Process for the preparation of Latanoprost | FINETECH LABORATORIES LTD (IL) | 2005-08-09 | — | — | US | disclosed |
| US-20040171873-A1 | Process for the preparation of 17-phenyl-18,19,20-thinor-pgf 2a and its derivatives | FINETECH PHARMACEUTICAL LTD. (IL) | 2004-09-02 | — | — | US | disclosed |
| EP-1397347-A2 | PREPARATION OF 17-PHENYL- 18, 19, 20- TRINOR-PGF2A AND ITS DERIVATIVES | Finetech Laboratories Ltd. (IL) | 2004-03-17 | — | — | EP | disclosed |
| US-20030149294-A1 | Process for the preparation of latanoprost | FINETECH PHARMACEUTICALS LTD. (IL) | 2003-08-07 | — | — | US | disclosed |
| WO-2002096868-A2 | PREPARATION OF 17-PHENYL- 18, 19, 20- TRINOR-PGF2A AND ITS DERIVATIVES | FINETECH LABORATORIES LTD. (IL) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171873-A1 | Process for the preparation of 17-phenyl-18,19,20-thinor-pgf 2a and its derivatives | PTGIS, PTGS2, PTGES2 | HDAC3 4672/4885HDAC4 4339/4885HDAC1 4787/4885 |
| US-20030149294-A1 | Process for the preparation of latanoprost | PTGIS, PTGIR, PTGES | HDAC3 4542/4885HDAC4 4415/4885HDAC1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.